Related Experiment Video
Updated: Oct 7, 2025
Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1
Published on: December 5, 2020
HIF-1α Is a Rational Target for Future Ovarian Cancer Therapies
Xin Wang1, Zhen-Wu Du2,3, Tian-Min Xu1
1Department of Obstetrics and Gynaecology, The Second Hospital of Jilin University, Changchun, China.
Abstract:
Ovarian cancer is the eighth most commonly diagnosed cancer among women worldwide. Even with the development of novel drugs, nearly one-half of the patients with ovarian cancer die within five years of diagnosis. These situations indicate the need for novel therapeutic agents for ovarian cancer. Increasing evidence has shown that hypoxia-inducible factor-1α(HIF-1α) plays an important role in promoting malignant cell chemoresistance, tumour metastasis, angiogenesis, immunosuppression and intercellular interactions. The unique microenvironment, crosstalk and/or interaction between cells and other characteristics of ovarian cancer can influence therapeutic efficiency or promote the disease progression. Inhibition of the expression or activity of HIF-1α can directly or indirectly enhance the therapeutic responsiveness of tumour cells. Therefore, it is reasonable to consider HIF-1α as a potential therapeutic target for ovarian cancer. In this paper, we summarize the latest research on the role of HIF-1α and molecules which can inhibit HIF-1α expression directly or indirectly in ovarian cancer, and drug clinical trials about the HIF-1α inhibitors in ovarian cancer or other solid malignant tumours.
Insights
Hypoxia-inducible factor-1α (HIF-1α) drives ovarian cancer progression and resistance to treatment. Inhibiting HIF-1α shows promise as a novel therapeutic strategy for improving patient outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Ovarian cancer remains a leading cause of cancer death in women globally.
- Despite advances in treatment, patient survival rates are limited, highlighting the need for new therapeutic approaches.
- Hypoxia-inducible factor-1α (HIF-1α) is increasingly recognized for its role in promoting cancer malignancy.
Purpose of the Study:
- To review the critical role of HIF-1α in ovarian cancer.
- To explore molecules that inhibit HIF-1α expression or activity.
- To summarize clinical trials involving HIF-1α inhibitors in ovarian and other solid tumors.
Main Methods:
- Literature review of recent research on HIF-1α in ovarian cancer.
- Analysis of studies investigating HIF-1α inhibitors.
- Examination of clinical trial data for HIF-1α targeting agents.
Main Results:
- HIF-1α contributes to chemoresistance, metastasis, angiogenesis, and immune evasion in ovarian cancer.
- Inhibition of HIF-1α can enhance the sensitivity of tumor cells to therapies.
- Several molecules targeting HIF-1α are under investigation for their therapeutic potential.
Conclusions:
- HIF-1α is a significant therapeutic target for ovarian cancer.
- Targeting HIF-1α offers a promising strategy to overcome treatment resistance and improve patient survival.
- Further research and clinical trials are warranted to develop effective HIF-1α inhibitors for ovarian cancer treatment.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:24Regulation of Angiogenesis and Blood Supply
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...
02:38Mitogens and the Cell Cycle